Checkmate Pharmaceuticals Inc

NASDAQ:CMPI  
6.74
+0.57 (+9.24%)
Regulatory, Earnings Announcements

Checkmate Pharmaceuticals Says On Track To Initiate Planned New Clinical Trials In Melanoma And Head And Neck Cancer

Published: 09/18/2020 11:31 GMT
Checkmate Pharmaceuticals Inc (CMPI) - Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress.
Checkmate Pharmaceuticals Inc - Cash and Cash Equivalents Were $80.3 Million As of June 30, 2020.
Checkmate Pharmaceuticals Inc - on Track to Initiate Planned New Clinical Trials in Melanoma and Head and Neck Cancer.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.65

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.